3D Full-Thickness Skin Model Services

The adaptation is documented as part of the applicability domain of the resulting data:

• Probe and fixture - a small-aperture probe matched to the usable surface of the tissue insert is used, with the insert held in a rigid fixture that constrains the carrier, so that measured deformation derives from the tissue rather than from displacement of the support.
• Curve handling - each measurement comprises consecutive suction/relaxation curves, of which the first is discarded. Published methodology shows the first curve differs significantly from subsequent curves while curves 2–4 are statistically homogeneous; discarding it removes the dominant source of intra-site variability.
• Parameter selection - R2, R5 and R7 are dimensionless ratios, independent of absolute deformation amplitude. Amplitude-based parameters are not used, as absolute penetration depth in a construct of this thickness is not comparable to in vivo values.
• Contraction control - fibroblast-mediated contraction of the dermal compartment alters thickness and pre-tension, so tissue dimensions are recorded at casting and at measurement, and tissues outside the pre-defined window are excluded before unblinding.
• Environmental control - measurements are taken at controlled temperature and humidity after a defined equilibration period, with surface moisture standardized across arms.

Data generated under this configuration supports comparison between concurrently measured arms. It is not intended for direct numerical comparison with in vivo suction-based mechanical parameters or with data from other model formats.

Histological endpoints are scored against pre-defined criteria fixed in the protocol before the study begins - for example epidermal thickness, stratum corneum continuity, presence of parakeratosis or spongiosis, and basal layer organization. Slides are coded so that the assessor is blinded to treatment allocation, and a proportion is independently re-scored to check assessor agreement. Where the endpoint supports it, image-analysis quantification (such as epidermal thickness measurement across defined fields) is reported alongside the categorical score. Histological findings are interpreted together with the functional and molecular endpoints rather than in isolation; where the three categories diverge, this is stated in the report rather than resolved in favor of the strongest signal.

We control donor-to-donor and batch-to-batch variation through:

• Standardized Cell Banking: Extensively characterized, pooled primary human cells are used to minimize genetic variability.
• Defined Matrices: Dermal compartments use highly purified, standardized collagen or synthetic scaffolds, integrated as qualified compliant consumables.
• Strict SOPs: All models are constructed in an ISO-certified environment using automated or semi-automated processes. A comprehensive Certificate of Analysis (CoA) with histological validation (H&E staining showing distinct epidermal layers) is provided for every study.

Yes. We offer 3D Pigmented Skin Models constructed using primary human keratinocytes and melanocytes isolated from native human skin tissue. These models exhibit physiological melanin granule distribution, a fully stratified epidermal structure, and metabolic functions analogous to natural skin. They are used for in vitro skin-lightening (whitening) efficacy testing and for research into the mechanisms of pigmentation disorders and hyperpigmentation (dark spot) formation.

Yes. We also offer a 3D Corneal Epithelium Model constructed using human corneal epithelial cells. This model exhibits structural and functional characteristics similar to native human corneal tissue, including in vivo-like intercellular junctions such as desmosomes and hemidesmosomes, along with normal expression of cornea-specific keratins. It supports evaluation of the ocular irritation potential of cosmetics and chemicals, as well as safety and efficacy assessment of eye care products.

Yes. Extending healthy models to disease states remains an industry challenge, and we offer validated disease models including:

• Psoriasis & Atopic Dermatitis: Induced via defined cytokine cocktails to reproduce hyperproliferation, barrier dysfunction, and altered gene expression.
• Aging & Photoaging: Established using aged donor cells, advanced glycation end-products (AGEs), or controlled UVA/UVB irradiation, supporting anti-aging efficacy claims.

Traditional ex vivo skin has a short viability window, which limits chronic toxicity testing. Because our 3D full-thickness models are metabolically active and fully integrated, they can be maintained in culture for up to 3 to 4 weeks post-maturation. This extended lifespan allows repeated topical applications, long-term efficacy tracking, and chronic irritation or cumulative toxicity assessments.

Yes. Our 3D models follow principles aligned with OECD guidelines for skin testing (e.g., OECD 439 for In Vitro Skin Irritation and OECD 431 for Skin Corrosion). The resulting data provides scientific evidence for "animal-free" efficacy claims, supporting internal R&D decisions and marketing dossiers for cosmetic and dermatological products.